Article Text

Download PDFPDF

LSO-074 All-cause mortality and the incidence of cancer in patients with moderate-to-severe SLE: results from the British isles lupus assessment group biologics registry (BILAG-BR)
  1. Mia Rodziewicz1,
  2. Sarah Dyball1,
  3. Emily Sutton1,
  4. Stephen Mcdonald1,
  5. Ben Parker1,2 and
  6. Ian Bruce1,2
  1. 1Centre for Musculoskeletal Research, The University of Manchester, UK
  2. 2NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, UK


Background We aimed to characterise the all-cause mortality rate (MR) and the incidence of cancer in SLE patients receiving biologic and standard of care (SoC) therapies.

Methods Patients recruited to the BILAG-BR 2010–2021 were included. Demographic and clinical data were recorded at recruitment. Mortality and malignancy data were collected from study centres, the UK Office of National Statistics and the National Cancer Register. Cox regression models were used to estimate risk in biologic-treated patients compared to SoC. Mortality models were adjusted for age, gender, co-morbidity, SLICC damage index (SDI) and hydroxychloroquine (HCQ) use.

Results During follow-up, (1463 patients with 5,962 person years [pys]), 32 incident cancers occurred in 31 individuals, a median (IQR) of 1.31 (0.63–3.36) years after registration. Compared to the UK general population, the SIR (95% CI) was 1.21 (0.85–1.72). Using SoC as the comparator, the age and gender adjusted HR was 1.49 (0.57–3.92) for rituximab and 2.47 (0.57–10.58) for belimumab. Across the whole cohort, associated risk factors (table 1), included age at recruitment (HR 1.05 [1.02- 1.08]) and male sex (HR 2.68 [1.13–6.41]).

Following registration, 54 deaths occurred after a median of 1.8 (0.8–3.3) years. The standardised MR was 4.74 (3.63–6.19). The most common causes of death were infection (22, 40.7%), SLE (11, 20.3%) and cancer (6, 11.1%). MR was 3.3 (1.3–8.9) per 1000 py in the SoC, 11.3 (8.5–15.0) in the rituximab and 2.5 (0.4–17.9) in the belimumab group. Risk factors included age at recruitment (HR 1.07 [1.05–1.09]) and SDI (HR 1.34 [1.08–1.67]. HCQ use was protective (HR 0.30 [0.14–0.65]). In multivariate analysis, compared to SoC, risk was similar in rituximab (HR 2.36 [0.69–8.10) and belimumab groups (HR 1.41 [0.14–14.14]).

Conclusions Although overall numbers are low, mortality rate and incidence of cancer appears to be broadly similar in SoC, rituximab and belimumab treated patients.

Abstract LSO-074 Table 1

Risk factors associated with risk of cancer and death in a cohort of patientswith moderate-severe SLE

  • Systemic lupus erythematosus
  • Real-world evidence
  • mortality

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.